ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Statistics
Want to see HK:1541 full AI Analyst Report?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Stock Statistics & Valuation Metrics
Total Valuation
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has a market cap or net worth of HKD 1.23B. The enterprise value is HKD 992.18M.
- Market Cap
- HKD 1.23B
- Enterprise Value
- HKD 992.18M
Share Statistics
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has 420,477,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 420,477,300
- Owned by Insiders
- ―
- Owned by Institutions
- 0.19%
Financial Efficiency
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -21.33%.
- Return on Equity (ROE)
- -0.27
- Return on Assets (ROA)
- -0.19
- Return on Invested Capital (ROIC)
- -21.33%
- Return on Capital Employed (ROCE)
- -0.26
- Revenue Per Employee
- 744.06K
- Profits Per Employee
- -1.05M
- Employee Count
- 202
- Asset Turnover
- 0.14
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H is -4.56. ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s PEG ratio is -0.14.
- PE Ratio
- -4.56
- PS Ratio
- 6.84
- PB Ratio
- 1.67
- Price to FCF
- -4.42
- Price to Operating Cash Flow
- -4.48
- PEG Ratio
- -0.14
Income Statement
In the last 12 months, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had revenue of 150.30M and earned -212.92M in profits. Earnings per share was -0.51.
- Revenue
- 150.30M
- Gross Profit
- 134.99M
- Operating Income
- -217.26M
- Pretax Income
- -213.58M
- Net Income
- -212.92M
- EBITDA
- -203.03M
- Earnings Per Share (EPS)
- -0.51
Cash Flow
In the last 12 months, operating cash flow was -232.80M and capital expenditures -1.95M, giving a free cash flow of -234.76M billion.
- Operating Cash Flow
- -232.80M
- Free Cash Flow
- -234.76M
- Free Cash Flow per Share
- -0.54
Dividends & Yields
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -22.65%
- Earnings Yield
- -21.98%
Stock Price Statistics
- Beta
- 0.70
- 52-Week Price Change
- -60.87%
- 50-Day Moving Average
- 3.11
- 200-Day Moving Average
- 3.79
- Relative Strength Index (RSI)
- 45.08
- Average Volume (3m)
- 464.17K
Important Dates
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Mar 30, 2027
- Ex-Dividend Date
- ―
Financial Position
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H as a current ratio of 3.83, with Debt / Equity ratio of 28.81%
- Current Ratio
- 3.83
- Quick Ratio
- 3.83
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- 2.22
- Interest Coverage Ratio
- -42.05
Taxes
In the past 12 months, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has paid 28.25K in taxes.
- Income Tax
- 28.25K
- Effective Tax Rate
- -0.00
Enterprise Valuation
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H EV to EBITDA ratio is -3.70, with an EV/FCF ratio of -3.20.
- EV to Sales
- 4.96
- EV to EBITDA
- -3.70
- EV to Free Cash Flow
- -3.20
- EV to Operating Cash Flow
- -3.23
Balance Sheet
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has HKD 946.44M in cash and marketable securities with HKD 363.12M in debt, giving a net cash position of HKD 583.33M billion.
- Cash & Marketable Securities
- HKD 946.44M
- Total Debt
- HKD 363.12M
- Net Cash
- HKD 583.33M
- Net Cash Per Share
- HKD 1.39
- Tangible Book Value Per Share
- HKD 1.44
Margins
Gross margin is 94.57%, with operating margin of -134.78%, and net profit margin of -151.13%.
- Gross Margin
- 94.57%
- Operating Margin
- -134.78%
- Pretax Margin
- -152.33%
- Net Profit Margin
- -151.13%
- EBITDA Margin
- -134.01%
- EBIT Margin
- -143.42%
Analyst Forecast
The average price target for ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 28.93%
- EPS Growth Forecast
- 27.27%
Scores
- Smart Score
- 1
- AI Score
- 46

